Gastroenterology

  • Home
  • Gastroenterology
Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   PD-L1 Positive;   Stage IIIB Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
Sponsor:   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

April 10, 2019 / by / in
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Condition:   Pneumococcal Disease
Interventions:   Biological: 20vPnC;   Biological: 13vPnC;   Biological: PPSV23;   Other: Saline
Sponsor:   Pfizer
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

February 27, 2019 / by / in
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Condition:   Pneumococcal Disease
Interventions:   Biological: 13vPnC;   Biological: PPSV23;   Biological: 20vPnC
Sponsor:   Pfizer
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

February 25, 2019 / by / in
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
Intervention:   Drug: Rucaparib
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

February 20, 2019 / by / in